ArticleCureus2026
Add-On Spironolactone for Persistent Proteinuria After Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Patients With Diabetic Kidney Disease: A Retrospective Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the widespread use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), many patients with diabetic kidney disease continue to exhibit persistent proteinuria, highlighting an unmet clinical need for effective add-on therapies. Non-steroidal mineralocorticoid receptor antagonists (MRA) such as finerenone have recently shown benefits; however, the role of classical steroidal agents like spironolactone in this setting remains unclear.
methodsWe retrospectively analyzed 29 stable patients with type 2 diabetes mellitus (T2DM) treated at Jinnouchi Hospital who exhibited persistent proteinuria (urinary protein-to-creatinine ratio (UPCR): A2-A3; >0.15 g/g creatinine) despite more than six months of SGLT2i therapy and subsequently received add-on spironolactone for 12 months. Clinical parameters, including UPCR and estimated glomerular filtration rate (eGFR), were assessed 12 months before and at three, six, and 12 months after initiation of spironolactone therapy. We evaluated the effects of spironolactone on changes in proteinuria and the annual rate of eGFR decline.
resultsThe baseline UPCR (median and interquartile range (IQR)) was 0.70 (0.40-1.27) g/g creatinine, and eGFR (mean ± standard deviation) was 49.1±16.9 mL/min/1.73 m². UPCR significantly decreased to 0.15 (0.12-0.30) g/g creatinine at 12 months after spironolactone initiation (p<0.001). Although an initial decline in eGFR was observed within three months (initial eGFR dip; -9.3%), the annual rate of eGFR decline (median (IQR)) improved from -2.2 (-7.0 to -0.9) to 1.3 (-1.5 to 3.3) mL/min/1.73 m²/year during months 3-12 after spironolactone therapy (p=0.001).
conclusionAdd-on spironolactone therapy may provide additional renoprotective effects in patients with T2DM and persistent proteinuria despite SGLT2i treatment. Although spironolactone is an older and inexpensive steroidal MRA, it may still represent a clinically meaningful therapeutic option in the contemporary SGLT2i era.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.